- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Benign Prostatic Hyperplasia Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Benign Prostatic Hyperplasia Therapeutics market size is estimated to be worth US$ 6664.1 million in 2021 and is forecast to a readjusted size of USD 8338.4 million by 2028 with a CAGR of 3.3% during review period. Mono Drug Therapy accounting for % of the Benign Prostatic Hyperplasia Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Alpha Blocker segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Benign Prostatic Hyperplasia Therapeutics include Abbott Laboratories, Allergan plc, Astellas Pharma, Boehringer Ingelheim Pharma GmbH and Co. KG, and Eli Lilly and Company, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Benign Prostatic Hyperplasia Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
Market segment by Application, can be divided into
Mono Drug Therapy
Combination Drug Therapy
Market segment by players, this report covers
Abbott Laboratories
Allergan plc
Astellas Pharma
Boehringer Ingelheim Pharma GmbH and Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck and Co.
Pfizer
Sanofi
Teva Pharmaceutical Industries Limited
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Benign Prostatic Hyperplasia Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Benign Prostatic Hyperplasia Therapeutics, with revenue, gross margin and global market share of Benign Prostatic Hyperplasia Therapeutics from 2019 to 2022.
Chapter 3, the Benign Prostatic Hyperplasia Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Benign Prostatic Hyperplasia Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Benign Prostatic Hyperplasia Therapeutics research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Therapeutics
1.2 Classification of Benign Prostatic Hyperplasia Therapeutics by Type
1.2.1 Overview: Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type in 2021
1.2.3 Alpha Blocker
1.2.4 5-Alpha Reductase Inhibitor
1.2.5 Phosphodiesterase-5 Inhibitor
1.2.6 Others
1.3 Global Benign Prostatic Hyperplasia Therapeutics Market by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Mono Drug Therapy
1.3.3 Combination Drug Therapy
1.4 Global Benign Prostatic Hyperplasia Therapeutics Market Size & Forecast
1.5 Global Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast by Region
1.5.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region, (2017-2022)
1.5.3 North America Benign Prostatic Hyperplasia Therapeutics Market Size and Prospect (2017-2028)
1.5.4 Europe Benign Prostatic Hyperplasia Therapeutics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size and Prospect (2017-2028)
1.5.6 South America Benign Prostatic Hyperplasia Therapeutics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Benign Prostatic Hyperplasia Therapeutics Market Drivers
1.6.2 Benign Prostatic Hyperplasia Therapeutics Market Restraints
1.6.3 Benign Prostatic Hyperplasia Therapeutics Trends Analysis
2 Company Profiles
2.1 Abbott Laboratories
2.1.1 Abbott Laboratories Details
2.1.2 Abbott Laboratories Major Business
2.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.1.4 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Abbott Laboratories Recent Developments and Future Plans
2.2 Allergan plc
2.2.1 Allergan plc Details
2.2.2 Allergan plc Major Business
2.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.2.4 Allergan plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Allergan plc Recent Developments and Future Plans
2.3 Astellas Pharma
2.3.1 Astellas Pharma Details
2.3.2 Astellas Pharma Major Business
2.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.3.4 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Astellas Pharma Recent Developments and Future Plans
2.4 Boehringer Ingelheim Pharma GmbH and Co. KG
2.4.1 Boehringer Ingelheim Pharma GmbH and Co. KG Details
2.4.2 Boehringer Ingelheim Pharma GmbH and Co. KG Major Business
2.4.3 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.4.4 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments and Future Plans
2.5 Eli Lilly and Company
2.5.1 Eli Lilly and Company Details
2.5.2 Eli Lilly and Company Major Business
2.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.5.4 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Eli Lilly and Company Recent Developments and Future Plans
2.6 GlaxoSmithKline plc
2.6.1 GlaxoSmithKline plc Details
2.6.2 GlaxoSmithKline plc Major Business
2.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.6.4 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 GlaxoSmithKline plc Recent Developments and Future Plans
2.7 Merck and Co.
2.7.1 Merck and Co. Details
2.7.2 Merck and Co. Major Business
2.7.3 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.7.4 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Merck and Co. Recent Developments and Future Plans
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business
2.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.8.4 Pfizer Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Pfizer Recent Developments and Future Plans
2.9 Sanofi
2.9.1 Sanofi Details
2.9.2 Sanofi Major Business
2.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.9.4 Sanofi Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Sanofi Recent Developments and Future Plans
2.10 Teva Pharmaceutical Industries Limited
2.10.1 Teva Pharmaceutical Industries Limited Details
2.10.2 Teva Pharmaceutical Industries Limited Major Business
2.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.10.4 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Teva Pharmaceutical Industries Limited Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Benign Prostatic Hyperplasia Therapeutics Players Market Share in 2021
3.2.2 Top 10 Benign Prostatic Hyperplasia Therapeutics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Benign Prostatic Hyperplasia Therapeutics Players Head Office, Products and Services Provided
3.4 Benign Prostatic Hyperplasia Therapeutics Mergers & Acquisitions
3.5 Benign Prostatic Hyperplasia Therapeutics New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Market Share by Type (2017-2022)
4.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Application (2017-2022)
5.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2017-2028)
6.2 North America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2017-2028)
6.3 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country
6.3.1 North America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2017-2028)
6.3.2 United States Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
6.3.3 Canada Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
6.3.4 Mexico Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2017-2028)
7.2 Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2017-2028)
7.3 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country
7.3.1 Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2017-2028)
7.3.2 Germany Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
7.3.3 France Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
7.3.5 Russia Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
7.3.6 Italy Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2017-2028)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2017-2028)
8.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region
8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Region (2017-2028)
8.3.2 China Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
8.3.3 Japan Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
8.3.4 South Korea Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
8.3.5 India Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
8.3.7 Australia Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2017-2028)
9.2 South America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2017-2028)
9.3 South America Benign Prostatic Hyperplasia Therapeutics Market Size by Country
9.3.1 South America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2017-2028)
9.3.2 Brazil Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
9.3.3 Argentina Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2017-2028)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2017-2028)
10.3 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country
10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2017-2028)
10.3.2 Turkey Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
10.3.4 UAE Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Region (2023-2028)
Table 6. Abbott Laboratories Corporate Information, Head Office, and Major Competitors
Table 7. Abbott Laboratories Major Business
Table 8. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 9. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Allergan plc Corporate Information, Head Office, and Major Competitors
Table 11. Allergan plc Major Business
Table 12. Allergan plc Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 13. Allergan plc Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Astellas Pharma Corporate Information, Head Office, and Major Competitors
Table 15. Astellas Pharma Major Business
Table 16. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 17. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Boehringer Ingelheim Pharma GmbH and Co. KG Corporate Information, Head Office, and Major Competitors
Table 19. Boehringer Ingelheim Pharma GmbH and Co. KG Major Business
Table 20. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 21. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 23. Eli Lilly and Company Major Business
Table 24. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 25. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. GlaxoSmithKline plc Corporate Information, Head Office, and Major Competitors
Table 27. GlaxoSmithKline plc Major Business
Table 28. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 29. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Merck and Co. Corporate Information, Head Office, and Major Competitors
Table 31. Merck and Co. Major Business
Table 32. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 33. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Pfizer Corporate Information, Head Office, and Major Competitors
Table 35. Pfizer Major Business
Table 36. Pfizer Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 37. Pfizer Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Sanofi Corporate Information, Head Office, and Major Competitors
Table 39. Sanofi Major Business
Table 40. Sanofi Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 41. Sanofi Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Teva Pharmaceutical Industries Limited Corporate Information, Head Office, and Major Competitors
Table 43. Teva Pharmaceutical Industries Limited Major Business
Table 44. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 45. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Global Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 47. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 48. Breakdown of Benign Prostatic Hyperplasia Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Benign Prostatic Hyperplasia Therapeutics Players Head Office, Products and Services Provided
Table 50. Benign Prostatic Hyperplasia Therapeutics Mergers & Acquisitions in the Past Five Years
Table 51. Benign Prostatic Hyperplasia Therapeutics New Entrants and Expansion Plans
Table 52. Global Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) by Type (2017-2022)
Table 53. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Type (2017-2022)
Table 54. Global Benign Prostatic Hyperplasia Therapeutics Revenue Forecast by Type (2023-2028)
Table 55. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2017-2022)
Table 56. Global Benign Prostatic Hyperplasia Therapeutics Revenue Forecast by Application (2023-2028)
Table 57. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 58. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 59. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 60. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 61. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 62. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 63. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 64. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 65. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 66. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 67. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 68. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 69. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 70. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 71. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 72. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 73. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 74. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 75. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 76. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 77. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 78. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 79. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 80. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 81. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 82. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 83. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 84. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 85. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 86. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Benign Prostatic Hyperplasia Therapeutics Picture
Figure 2. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type in 2021
Figure 3. Alpha Blocker
Figure 4. 5-Alpha Reductase Inhibitor
Figure 5. Phosphodiesterase-5 Inhibitor
Figure 6. Others
Figure 7. Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Application in 2021
Figure 8. Mono Drug Therapy Picture
Figure 9. Combination Drug Therapy Picture
Figure 10. Global Benign Prostatic Hyperplasia Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 11. Global Benign Prostatic Hyperplasia Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Region (2017-2028)
Figure 13. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Region in 2021
Figure 14. North America Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Europe Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. South America Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Benign Prostatic Hyperplasia Therapeutics Market Drivers
Figure 20. Benign Prostatic Hyperplasia Therapeutics Market Restraints
Figure 21. Benign Prostatic Hyperplasia Therapeutics Market Trends
Figure 22. Abbott Laboratories Recent Developments and Future Plans
Figure 23. Allergan plc Recent Developments and Future Plans
Figure 24. Astellas Pharma Recent Developments and Future Plans
Figure 25. Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments and Future Plans
Figure 26. Eli Lilly and Company Recent Developments and Future Plans
Figure 27. GlaxoSmithKline plc Recent Developments and Future Plans
Figure 28. Merck and Co. Recent Developments and Future Plans
Figure 29. Pfizer Recent Developments and Future Plans
Figure 30. Sanofi Recent Developments and Future Plans
Figure 31. Teva Pharmaceutical Industries Limited Recent Developments and Future Plans
Figure 32. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Players in 2021
Figure 33. Benign Prostatic Hyperplasia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 34. Global Top 3 Players Benign Prostatic Hyperplasia Therapeutics Revenue Market Share in 2021
Figure 35. Global Top 10 Players Benign Prostatic Hyperplasia Therapeutics Revenue Market Share in 2021
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 37. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Type in 2021
Figure 38. Global Benign Prostatic Hyperplasia Therapeutics Market Share Forecast by Type (2023-2028)
Figure 39. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Application in 2021
Figure 40. Global Benign Prostatic Hyperplasia Therapeutics Market Share Forecast by Application (2023-2028)
Figure 41. North America Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2017-2028)
Figure 42. North America Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2017-2028)
Figure 43. North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Country (2017-2028)
Figure 44. United States Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2017-2028)
Figure 48. Europe Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2017-2028)
Figure 49. Europe Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Country (2017-2028)
Figure 50. Germany Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2017-2028)
Figure 56. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Region (2017-2028)
Figure 58. China Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. South Korea Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2017-2028)
Figure 65. South America Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2017-2028)
Figure 66. South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2017-2028)
Figure 70. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2017-2028)
Figure 71. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Country (2017-2028)
Figure 72. Turkey Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. UAE Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
